Download PDF
Digestive Disease Interventions 2023; 07(01): 042-050
DOI: 10.1055/s-0042-1760426
Review Article

Management of Patients with Synchronous Liver Colorectal Cancer Metastasis

Aleksandra Sidorova 
1   Department of Surgery, GMS Clinic and Hospitals, Moscow, Russia
,
Olga Melekhina 
2   Department of Interventional Radiology, Moscow Clinical Scientific Center, Moscow, Russia
,
Badma Bashankaev 
1   Department of Surgery, GMS Clinic and Hospitals, Moscow, Russia
3   Moscow State University of Medicine and Dentistry, Moscow, Russia
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Half of patients with colorectal cancer face liver metastasis. Tactically different approaches to the treatment of hepatic metastases, including using minimally invasive surgical techniques, have proven their effectiveness in improving oncological results. The correct choice of surgical treatment method depending on the number, localization, size of metastases, and their response to chemotherapy plays a crucial role in the further risks of disease progression. Liver resection is the standard of surgical treatment. If for some reason it is impossible to perform it, then the choice of the method of surgical treatment is performed among various methods of ablation and radiation therapy. The possibilities of intra-arterial chemotherapy, chemoembolization, and radioembolization are realized with chemoresistance and unresectability of foci for all types of surgery.

Keywords

colorectal cancer - liver metastasis - synchronous metastasis


Publication History

Received: 04 June 2022

Accepted: 05 December 2022

Article published online:
19 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244 (02) 254-259
    CrossrefPubMedGoogle Scholar
  • 2 Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006; 93 (04) 465-474
    CrossrefPubMedGoogle Scholar
  • 3 Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016; 22 (11) 3127-3149
    CrossrefPubMedGoogle Scholar
  • 4 Mekenkamp LJM, Koopman M, Teerenstra S. et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103 (02) 159-164
    CrossrefPubMedGoogle Scholar
  • 5 Sutphin PD, Ganguli S. Interventional treatment of hepatic metastases from colorectal cancer. Semin Intervent Radiol 2020; 37 (05) 492-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Creasy JM, Sadot E, Koerkamp BG. et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery 2018; 163 (06) 1238-1244
    CrossrefPubMedGoogle Scholar
  • 7 Ivey GD, Johnston FM, Azad NS, Christenson ES, Lafaro KJ, Shubert CR. Current surgical management strategies for colorectal cancer liver metastases. Cancers (Basel) 2022; 14 (04) 1063
    CrossrefPubMedGoogle Scholar
  • 8 Hosokawa I, Allard MA, Mirza DF. et al. Outcomes of parenchyma-preserving hepatectomy and right hepatectomy for solitary small colorectal liver metastasis: a LiverMetSurvey study. Surgery 2017; 162 (02) 223-232
    CrossrefPubMedGoogle Scholar
  • 9 Reddy SK, Pawlik TM, Zorzi D. et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14 (12) 3481-3491
    CrossrefPubMedGoogle Scholar
  • 10 Shubert CR, Habermann EB, Bergquist JR. et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection. J Gastrointest Surg 2015; 19 (11) 1982-1994
    CrossrefPubMedGoogle Scholar
  • 11 Silberhumer GR, Paty PB, Denton B. et al. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery 2016; 160 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 12 Brouquet A, Mortenson MM, Vauthey JN. et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. J Am Coll Surg 2010; 210 (06) 934-941
    CrossrefPubMedGoogle Scholar
  • 13 Lykoudis PM, O'Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 2014; 101 (06) 605-612
    CrossrefPubMedGoogle Scholar
  • 14 Krell RW, D'Angelica MI. Treatment sequencing for simultaneous colorectal liver metastases. J Surg Oncol 2019; 119 (05) 583-593
    CrossrefPubMedGoogle Scholar
  • 15 Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg 2013; 148 (04) 385-391
    CrossrefPubMedGoogle Scholar
  • 16 Crocetti L, de Baére T, Pereira PL, Tarantino FP. CIRSE standards of practice on thermal ablation of liver tumours. Cardiovasc Intervent Radiol 2020; 43 (07) 951-962
    CrossrefPubMedGoogle Scholar
  • 17 Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265 (03) 958-968
    CrossrefPubMedGoogle Scholar
  • 18 Ruers T, Van Coevorden F, Punt CJ. et al; European Organisation for Research and Treatment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017; 109 (09) djx015
    CrossrefPubMedGoogle Scholar
  • 19 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (08) 1386-1422
    CrossrefPubMedGoogle Scholar
  • 20 Ahmed M, Solbiati L, Brace CL. et al; International Working Group on Image-guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology 2014; 273 (01) 241-260
    CrossrefPubMedGoogle Scholar
  • 21 Takahashi H, Berber E. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobiliary Surg Nutr 2020; 9 (01) 49-58
    CrossrefPubMedGoogle Scholar
  • 22 Seror O. Ablative therapies: advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient?. Diagn Interv Imaging 2015; 96 (06) 617-624
    CrossrefPubMedGoogle Scholar
  • 23 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19 (05) 1206-1213
    CrossrefPubMedGoogle Scholar
  • 24 Shady W, Petre EN, Gonen M. et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes-a 10-year experience at a single center. Radiology 2016; 278 (02) 601-611
    CrossrefPubMedGoogle Scholar
  • 25 Wong SL, Mangu PB, Choti MA. et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28 (03) 493-508
    CrossrefPubMedGoogle Scholar
  • 26 Gillams A, Goldberg N, Ahmed M. et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25 (12) 3438-3454
    CrossrefPubMedGoogle Scholar
  • 27 Birsen O, Aliyev S, Aksoy E. et al. A critical analysis of postoperative morbidity and mortality after laparoscopic radiofrequency ablation of liver tumors. Ann Surg Oncol 2014; 21 (06) 1834-1840
    CrossrefPubMedGoogle Scholar
  • 28 Mulier S, Mulier P, Ni Y. et al. Complications of radiofrequency coagulation of liver tumours. World J Hepatol 2014; 6 (03) 107-113
    PubMedGoogle Scholar
  • 29 Ruers T, Punt C, Van Coevorden F. et al; EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23 (10) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 30 Puijk RS, Ruarus AH, Vroomen LGPH. et al; COLLISION Trial Group. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18 (01) 821
    CrossrefPubMedGoogle Scholar
  • 31 Karanicolas PJ, Jarnagin WR, Gonen M. et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg 2013; 148 (07) 597-601
    CrossrefPubMedGoogle Scholar
  • 32 Van Tilborg AAJM, Meijerink MR, Sietses C. et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol 2011; 84 (1002): 556-565
    CrossrefPubMedGoogle Scholar
  • 33 Benhaim L, El Hajjam M, Malafosse R. et al. Radiofrequency ablation for colorectal cancer liver metastases initially greater than 25 mm but downsized by neo-adjuvant chemotherapy is associated with increased rate of local tumor progression. HPB (Oxford) 2018; 20 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 34 Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol 2015; 26 (08) 1139-1146.e2
    CrossrefPubMedGoogle Scholar
  • 35 Mimmo A, Pegoraro F, Rhaiem R. et al. Microwave ablation for colorectal liver metastases: a systematic review and pooled oncological analyses. Cancers (Basel) 2022; 14 (05) 1305
    CrossrefPubMedGoogle Scholar
  • 36 McEachron KR, Ankeny JS, Robbins A. et al. Surgical microwave ablation of otherwise non-resectable colorectal cancer liver metastases: expanding opportunities for long term survival. Surg Oncol 2021; 36: 61-64
    CrossrefPubMedGoogle Scholar
  • 37 Liang P, Dong B, Yu X. et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. AJR Am J Roentgenol 2003; 181 (05) 1319-1325
    CrossrefPubMedGoogle Scholar
  • 38 Qin S, Liu GJ, Huang M. et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. Int J Hyperthermia 2019; 36 (01) 36-43
    CrossrefPubMedGoogle Scholar
  • 39 Leung U, Kuk D, D'Angelica MI. et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015; 102 (01) 85-91
    CrossrefPubMedGoogle Scholar
  • 40 Zorbas G, Samaras T. A study of the sink effect by blood vessels in radiofrequency ablation. Comput Biol Med 2015; 57: 182-186
    CrossrefPubMedGoogle Scholar
  • 41 Ridouani F, Ghosn M, Cornelis F. et al. Ablation zone involution of liver tumors is faster in patients treated with irreversible electroporation than microwave ablation. Medicina 2021; 57 (09) 877
    CrossrefPubMedGoogle Scholar
  • 42 Silk MT, Wimmer T, Lee KS. et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 2014; 25 (01) 112-118
    CrossrefPubMedGoogle Scholar
  • 43 Kingham TP, Karkar AM, D'Angelica MI. et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (03) 379-387
    CrossrefPubMedGoogle Scholar
  • 44 Scheffer HJ, Nielsen K, van Tilborg AA. et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 2014; 24 (10) 2467-2475
    CrossrefPubMedGoogle Scholar
  • 45 Saini A, Breen I, Alzubaidi S. et al. Irreversible electroporation in liver cancers and whole organ engineering. J Clin Med 2019; 8 (01) 22
    CrossrefPubMedGoogle Scholar
  • 46 Vogl TJ, Dommermuth A, Heinle B. et al. Colorectal cancer liver metastases: long-term survival and progression-free survival after thermal ablation using magnetic resonance-guided laser-induced interstitial thermotherapy in 594 patients: analysis of prognostic factors. Invest Radiol 2014; 49 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 47 Elhelf IAS, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M. High intensity focused ultrasound: the fundamentals, clinical applications and research trends. Diagn Interv Imaging 2018; 99 (06) 349-359
    CrossrefPubMedGoogle Scholar
  • 48 Hsiao YH, Kuo SJ, Tsai HD, Chou MC, Yeh GP. Clinical application of high-intensity focused ultrasound in cancer therapy. J Cancer 2016; 7 (03) 225-231
    CrossrefPubMedGoogle Scholar
  • 49 Dupré A, Melodelima D, Pérol D. et al. First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases: a phase I-IIa study. PLoS One 2015; 10 (02) e0118212
    CrossrefPubMedGoogle Scholar
  • 50 Melodelima D, N'Djin WA, Parmentier H, Rivoire M, Chapelon JY. Toric HIFU transducer for large thermal ablation. / 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society; 2007
    PubMedGoogle Scholar
  • 51 Zhou Y-F. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol 2011; 2 (01) 8-27
    CrossrefPubMedGoogle Scholar
  • 52 Yang T, Ng DM, Du N. et al. HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial. Surg Endosc 2021; 35 (05) 2306-2315
    CrossrefPubMedGoogle Scholar
  • 53 Chan ACY, Cheung TT, Fan ST. et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg 2013; 257 (04) 686-692
    CrossrefPubMedGoogle Scholar
  • 54 Ng KKC, Poon RT, Chan SC. et al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg 2011; 253 (05) 981-987
    CrossrefPubMedGoogle Scholar
  • 55 Aarts BM, Klompenhouwer EG, Rice SL. et al. Cryoablation and immunotherapy: an overview of evidence on its synergy. Insights Imaging 2019; 10 (01) 53
    CrossrefPubMedGoogle Scholar
  • 56 Niu L, Zhou L, Xu K, Mu F. Cryosurgery for colorectal liver metastases. Ann Palliat Med 2013; 2 (03) 130-140
    PubMedGoogle Scholar
  • 57 Erinjeri JP, Clark TWI. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S187-S191
    CrossrefPubMedGoogle Scholar
  • 58 Seifert JK, France MP, Zhao J. et al. Large volume hepatic freezing: association with significant release of the cytokines interleukin-6 and tumor necrosis factor a in a rat model. World J Surg 2002; 26 (11) 1333-1341
    CrossrefPubMedGoogle Scholar
  • 59 Bala MM, Riemsma RP, Wolff R. et al. Cryotherapy for liver metastases. Cochrane Database Syst Rev 2019; 7 (07) CD009058
    PubMedGoogle Scholar
  • 60 Ren L, Zhu D, Benson III AB. et al; SINCE (Shanghai International Consensus Expert Group on Colorectal Liver Metastases) Group. Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). Eur J Surg Oncol 2020; 46 (06) 955-966
    CrossrefPubMedGoogle Scholar
  • 61 Aitken KL, Hawkins MA. Stereotactic body radiotherapy for liver metastases. Clin Oncol (R Coll Radiol) 2015; 27 (05) 307-315
    CrossrefPubMedGoogle Scholar
  • 62 Nieuwenhuizen S, Dijkstra M, Puijk RS. et al. Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam Core Registry. Cancers (Basel) 2021; 13 (17) 4303
    CrossrefPubMedGoogle Scholar
  • 63 Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70
    CrossrefPubMedGoogle Scholar
  • 64 Scorsetti M, Comito T, Tozzi A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015; 141 (03) 543-553
    CrossrefPubMedGoogle Scholar
  • 65 Kwan J, Pua U. Review of intra-arterial therapies for colorectal cancer liver metastasis. Cancers (Basel) 2021; 13 (06) 1-27
    CrossrefPubMedGoogle Scholar
  • 66 National Comprehensive Cancer Network. (referenced with permission from the NCCN Clinical Practice Guidelines in Oncology) NCCN Guidelines®. Colon Cancer Version 1.2022© National Comprehensive Cancer Network, Inc., 2022, All rights reserved. Accessed January 13, 2023 at: https://www.nccn.org/
    PubMedGoogle Scholar
  • 67 Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 03) iii1-iii9
    CrossrefPubMedGoogle Scholar
  • 68 Ackerman NB, Hechmer PA. The blood supply of experimental liver metastases. V. Increased tumor perfusion with epinephrine. Am J Surg 1980; 140 (05) 625-631
    CrossrefPubMedGoogle Scholar
  • 69 Thiels CA, D'Angelica MI. Hepatic artery infusion pumps. J Surg Oncol 2020; 122 (01) 70-77
    CrossrefPubMedGoogle Scholar
  • 70 Cercek A, Boucher TM, Gluskin JS. et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol 2016; 114 (06) 655-663
    CrossrefPubMedGoogle Scholar
  • 71 Groot Koerkamp B, Sadot E, Kemeny NE. et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol 2017; 35 (17) 1938-1944
    CrossrefPubMedGoogle Scholar
  • 72 Wáng YXJ, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015; 27 (02) 96-121
    PubMedGoogle Scholar
  • 73 Gruber-Rouh T, Naguib NN, Eichler K. et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer 2014; 134 (05) 1225-1231
    CrossrefPubMedGoogle Scholar
  • 74 Vogl TJ, Lahrsow M, Albrecht MH, Hammerstingl R, Thompson ZM, Gruber-Rouh T. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. Eur J Radiol 2018; 102: 138-145
    CrossrefPubMedGoogle Scholar
  • 75 Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. Surg Oncol 2017; 26 (03) 268-275
    CrossrefPubMedGoogle Scholar
  • 76 Martin II RCG, Scoggins CR, Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121 (20) 3649-3658
    CrossrefPubMedGoogle Scholar
  • 77 Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001; 46 (02) 487-498
    CrossrefPubMedGoogle Scholar
  • 78 Van Hazel G, Blackwell A, Anderson J. et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88 (02) 78-85
    CrossrefPubMedGoogle Scholar
  • 79 Hendlisz A, Van den Eynde M, Peeters M. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
    CrossrefPubMedGoogle Scholar